<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261338</url>
  </required_header>
  <id_info>
    <org_study_id>10100801 1R21ES019206-01</org_study_id>
    <secondary_id>1R21ES019206-01</secondary_id>
    <secondary_id>8 UL1 TR00007</secondary_id>
    <nct_id>NCT01261338</nct_id>
  </id_info>
  <brief_title>Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama</brief_title>
  <acronym>PCBs</acronym>
  <official_title>Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because of industrial pollution, a large number of people in Anniston, Alabama, have elevated&#xD;
      body burdens of the class of compounds known as polychlorinated biphenyls (PCBs). There is&#xD;
      evidence that these compounds are associated with risks to health including diabetes. There&#xD;
      is also evidence that the consumption of a non-absorbable dietary fat can reduce the level of&#xD;
      compounds like PCBs. This clinical trial will test the hypothesis that a non-absorbable&#xD;
      dietary fat can reduce the levels of PCBs in subjects in Anniston.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A clinical trial will be conducted which will test the use of a safe and minimally invasive&#xD;
      dietary intervention to enhance the removal of toxic polychlorinated biphenyls (PCBs) from&#xD;
      individuals with elevated levels of these compounds. To conduct this study, participants will&#xD;
      be recruited and enrolled in Anniston, Alabama, a community in which a significant portion of&#xD;
      the local population has been exposed to PCBs as a result of contaminated commercial waste.&#xD;
      Many of the residents of Anniston currently have markedly elevated blood and adipose tissue&#xD;
      PCB levels. In addition, these individuals have a several-fold increased prevalence of type-2&#xD;
      diabetes and are potentially at greater risk of other health disorders. .&#xD;
&#xD;
      A method was developed for adding a small amount of non-absorbable fat to the diet for use as&#xD;
      a therapeutic tool which hastens the elimination of persistent lipophilic compounds, such as&#xD;
      PCBs, in a safe manner. The rationale is based on the fact that once PCBs and other&#xD;
      organochlorine pollutants enter the body, they circulate among several organs including the&#xD;
      small intestine. Under normal circumstances, these compounds are reabsorbed from the&#xD;
      intestine and returned to the blood, and are thus prevented from being excreted in the feces.&#xD;
      The addition of a small amount of non-absorbable lipid in the diet provides a matrix for&#xD;
      physically retaining the pollutants within the intestinal lumen, which then allows the&#xD;
      pollutants to be excreted along with the lipid. Although the excretion on any given day is&#xD;
      relatively small, the cumulative excretion over the course of a year becomes clinically&#xD;
      significant. The Anniston population provides an ideal population to assess this intervention&#xD;
      in a meaningful way, and we have allied with a local community group to assist in the&#xD;
      recruitment of subjects and to carry out the relatively simple dietary manipulations required&#xD;
      for this study.&#xD;
&#xD;
      A double-blind, placebo controlled study of a non-absorbable fat in subjects known to have&#xD;
      elevated levels of PCBs will be conducted. The rate of change of the blood levels of PCBs in&#xD;
      these subjects will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline for Total PCB Levels</measure>
    <time_frame>one year</time_frame>
    <description>The outcome is the percent change in body burden of total PCB's measured over one year. Initially the percent of baseline is calculated as (value at one year / value at baseline) *100, then this is examined modeling over time as compared to the 100% at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Change of Lipid Adjusted PCB Levels</measure>
    <time_frame>One year</time_frame>
    <description>This is a measure of the change in body burden of PCBs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Toxic Effect of Other Corrosive Organic Compounds</condition>
  <arm_group>
    <arm_group_label>olestra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-absorbable fat administered in the form of 24 potato crisps per day (12 each with mid-day and evening meal) providing approximately 15g/day of olestra.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vegetable oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Absorbable fat administered in the form of 12 potato crisps per day (6 each with mid-day and evening meal) in order to match the caloric intake provided by the crisps with Olestra.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olestra</intervention_name>
    <description>non-absorbable dietary fat</description>
    <arm_group_label>Vegetable oil</arm_group_label>
    <arm_group_label>olestra</arm_group_label>
    <other_name>Olean</other_name>
    <other_name>non absorbable fat</other_name>
    <other_name>fat substitute</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elevated blood level of PCBs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Weight-loss medication&#xD;
&#xD;
          -  Gastrointestinal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald J Jandacek, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Anniston Foundation</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jandacek RJ, Heubi JE, Buckley DD, Khoury JC, Turner WE, Sj√∂din A, Olson JR, Shelton C, Helms K, Bailey TD, Carter S, Tso P, Pavuk M. Reduction of the body burden of PCBs and DDE by dietary intervention in a randomized trial. J Nutr Biochem. 2014 Apr;25(4):483-8. doi: 10.1016/j.jnutbio.2014.01.002. Epub 2014 Jan 29.</citation>
    <PMID>24629911</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 14, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <results_first_submitted>June 13, 2013</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2020</results_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCBs</keyword>
  <keyword>Olestra</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sucrose polyester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty-eight participants were recruited prior to April 2011.</recruitment_details>
      <pre_assignment_details>Participants were randomized into groups of 14 each, to receive either olestra and vegetable oil.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olestra</title>
          <description>Non-absorbable fat&#xD;
olestra : non-absorbable dietary fat</description>
        </group>
        <group group_id="P2">
          <title>Vegetable Oil</title>
          <description>absorbable fat</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14">One person in the olestra group started 4 months after the trial began.</participants>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olestra</title>
          <description>Non-absorbable fat&#xD;
olestra : non-absorbable dietary fat</description>
        </group>
        <group group_id="B2">
          <title>Vegetable Oil</title>
          <description>absorbable fat</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="9.6"/>
                    <measurement group_id="B2" value="61.0" spread="5.7"/>
                    <measurement group_id="B3" value="60.6" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline for Total PCB Levels</title>
        <description>The outcome is the percent change in body burden of total PCB's measured over one year. Initially the percent of baseline is calculated as (value at one year / value at baseline) *100, then this is examined modeling over time as compared to the 100% at baseline.</description>
        <time_frame>one year</time_frame>
        <population>Per protocol, based on elevated PCB levels</population>
        <group_list>
          <group group_id="O1">
            <title>Olestra</title>
            <description>Non-absorbable fat&#xD;
olestra : non-absorbable dietary fat</description>
          </group>
          <group group_id="O2">
            <title>Vegetable Oil</title>
            <description>absorbable fat</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline for Total PCB Levels</title>
          <description>The outcome is the percent change in body burden of total PCB's measured over one year. Initially the percent of baseline is calculated as (value at one year / value at baseline) *100, then this is examined modeling over time as compared to the 100% at baseline.</description>
          <population>Per protocol, based on elevated PCB levels</population>
          <units>% of baseline total PCBs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="3.4"/>
                    <measurement group_id="O2" value="96" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Change of Lipid Adjusted PCB Levels</title>
        <description>This is a measure of the change in body burden of PCBs</description>
        <time_frame>One year</time_frame>
        <population>All participants who completed the trial were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Olestra</title>
            <description>Non-absorbable fat&#xD;
olestra : non-absorbable dietary fat</description>
          </group>
          <group group_id="O2">
            <title>Vegetable Oil</title>
            <description>absorbable fat</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change of Lipid Adjusted PCB Levels</title>
          <description>This is a measure of the change in body burden of PCBs</description>
          <population>All participants who completed the trial were analyzed.</population>
          <units>ng/g lipid/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0829" spread="0.0357"/>
                    <measurement group_id="O2" value="-0.0413" spread="0.0408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Olestra</title>
          <description>Non-absorbable fat&#xD;
olestra : non-absorbable dietary fat</description>
        </group>
        <group group_id="E2">
          <title>Vegetable Oil</title>
          <description>absorbable fat</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for heart catheter</sub_title>
                <description>Participant had a previous history of heart disease. There as no relationship to the study treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chest pain and palpitations</sub_title>
                <description>Admitted to hospital</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Heart stent replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding Ulcers</sub_title>
                <description>Admitted to hospital</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular heartbeat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HGA1C elevated 6.4%</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Yeast Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in right hip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection in lining of rib cage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash on body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash on left and right anticubital area</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald J. Jandacek, PhD, Principal Investigator</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-558-5492</phone>
      <email>ronald.jandacek@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

